Eli Lilly (LLY): 3.82x Return Potential with BUY+ Signal
5 Year Overview
Right now, Eli Lilly and Company trades at $1,128. Based on its historical financial performance, the data points to $4,245 in five years — that is 3.82x, or 30.7% CAGR. The S&P 500 is projected at 1.87x over the same period. That puts it 195% ahead of the S&P 500 over the same period.
Why 3.82x in 5 Years?
EBITDA Method
The current EBITDA is $28B and is projected to reach $206B in five years — that is 53% annual growth. Applying the sector's historical multiple of 33x EV/EBITDA gives a price target of $7,659, or 6.79x from today — ahead of the market.
Eli Lilly's EBITDA has shown an impressive 53.43% CAGR, indicating robust operational leverage and strong demand for its innovative product pipeline. This suggests a powerful competitive position, allowing the company to translate revenue growth efficiently into profitability.
Free Cash Flow Method
The current free cash flow is $8.97B and is projected to reach $12B in five years — that is 53% annual growth. With an estimated FCF yield of 1.7%, this gives a price target of $830, or 0.74x from today — behind the market.
The company's Free Cash Flow has grown at a remarkable 53.43% CAGR, demonstrating its ability to generate substantial cash from operations. However, the current FCF yield of 0.89% suggests that a significant portion of this cash is being reinvested into the business or that the stock's valuation is quite high, reflecting future growth expectations.
Blending both methods, the data points to $4,245 in five years, against today's $1,128.
Is It Still Growing?
Revenue
In FY2025, Eli Lilly and Company brought in $65B in revenue, with a 5-year CAGR of 30%.
In FY2025, Eli Lilly experienced its most significant revenue surge, growing by 44.7% year-over-year. This impressive growth was primarily driven by the strong market adoption and increasing demand for its innovative new pharmaceutical products, particularly in the diabetes and obesity treatment categories.
EBITDA
In FY2025, EBITDA came in at $28B, with a 5-year CAGR of 53%.
Eli Lilly's EBITDA saw its most substantial increase in FY2025, with a remarkable 91.9% year-over-year growth. This significant margin expansion was largely fueled by strong operating leverage as blockbuster drug sales scaled up, allowing the company to convert higher revenues into disproportionately higher profits.
Free Cash Flow
Free cash flow for FY2025 was $8.97B, with a 5-year CAGR of 53%.
Eli Lilly experienced its most significant FCF dip in FY2023, with a substantial -86.2% year-over-year decrease, driven by a notable fall in operating cash flow and a surge in capital expenditures. This period likely reflects heavy investment in manufacturing capacity expansion and increased research and development to support the launch and scaling of its promising new drug pipeline.
Growth Overview
Eli Lilly's EBITDA CAGR of 53.43% significantly outpaces its Revenue CAGR of 30.43%, signaling a powerful story of margin expansion and operational efficiency. The Free Cash Flow CAGR also matches EBITDA at 53.43%, which suggests the company is effectively converting its growing profitability into cash, indicating a healthy balance between reinvestment and cash generation for investors.
Financial Health
19 out of 24 checks passed.
For the full breakdown, see the detailed analysis on StockSnack:
→ StockSnack Home — https://stocksnack.app
→ LLY Full Analysis (Pro Only) — https://stocksnack.app/screener/LLY
What Does Eli Lilly and Company Actually Do?
Top 1: Product — 89% of revenue.
This segment represents the vast majority of Eli Lilly's business, encompassing direct sales of its proprietary pharmaceutical drugs across various therapeutic areas.
Top 2: Collaboration and Other Revenue — 6.20% of revenue.
This segment includes income Eli Lilly generates from strategic partnerships, licensing agreements, and other non-product related activities.
Top 3: Jardiance — 5.00% of revenue.
This segment specifically details the revenue generated by Eli Lilly's key medication, Jardiance, which treats type 2 diabetes and heart failure.
Growth by Segment
All Segments by Growth (S&P 500 benchmark: 13% CAGR):
- Product: 45% CAGR ✓ — This segment represents the vast majority of Eli Lilly's business, encompassing direct sales of its proprietary pharmaceutical drugs across various therapeutic areas.
- Jardiance: 12% CAGR — This segment specifically details the revenue generated by Eli Lilly's key medication, Jardiance, which treats type 2 diabetes and heart failure.
- Collaboration and Other Revenue: -11% CAGR — This segment includes income Eli Lilly generates from strategic partnerships, licensing agreements, and other non-product related activities. On the other end, Collaboration and Other Revenue is the weakest performer at -11% CAGR. The "Collaboration and Other Revenue" segment, with a CAGR of -10.84%, is the slowest growing, likely due to the inherent variability and episodic nature of partnership milestones and licensing income.
Geographic Performance
Non-US: -1.8% CAGR · UNITED STATES: -19% CAGR
Valuation
So, is Eli Lilly and Company overvalued? We look at EV/EBITDA and FCF Yield.
EV/EBITDA
Eli Lilly and Company is valued at 33x EV/EBITDA. The sector's historical multiple is also 33x, making this the benchmark for our price target model.
FCF Yield
The current FCF yield is 0.9%, versus the industry average of 4.0%. Yield below peers suggests the market is pricing in stronger future growth.
With an EV/EBITDA multiple of 33.38, Eli Lilly appears to be trading at a premium, reflecting high growth expectations. The current FCF yield of 0.89% is significantly below the industry average of 3.98%, indicating that the stock's price is already demanding, leaving little margin of safety for new investors.
Verdict
The numbers give Eli Lilly and Company a final score of 93.8/100 — signal: BUY+
Eli Lilly and Company is projected to return 3.82x over 5 years, compared to the S&P 500's projected 1.87x over the same period.
While Eli Lilly demonstrates exceptional growth potential and a compelling projected total return of 3.82x, its current valuation appears quite demanding. The cumulative 5-year dividend of $60.26 per share significantly enhances the total return, providing an additional layer of investor benefit despite the high price.
→ Full analysis on StockSnack https://stocksnack.app
→ LLY Full Analysis (Members Only) https://stocksnack.app/screener/LLY
(Score: price projection 100/100 × 40% · growth quality 100/100 × 30% · financial health 79/100 × 30%)
Want to run the numbers yourself? Every stock in our screener gets the same projection — blending two valuation methods, benchmarked against the S&P 500. Explore all 500 stocks on StockSnack →
Not financial advice. Always do your own research.